BMPR1A Peptide
€100.00
In stock
SKU
350513
Protein Family: Cellular Antigens, Enzymes, Protein Kinases, Receptors and Channels
Pathway and Disease: Cancers, Signal Transduction, Signaling Molecules and Interaction
Alternate Names: Bone morphogenetic protein receptor type IA; Serine/threonine-protein kinase receptor R5; SKR5; Activin receptor-like kinase 3; ALK-3; CD292 antigen; BMPR1A; ACVRLK3
Accession No.: P36894, NP_004320
Description:
Upon ligand binding, BMPR1A forms a receptor complex consisting of two type II and two type I transmembrane Ser/Thr kinases. The type I receptors are activated by the type II receptors by using a phosphorylation mechanism, and subsequently bind SMAD transcriptional regulators. Defects in BMPR1A are the cause of juvenile polyposis syndrome, Cowden disease and hereditary mixed polyposis syndrome 2, which lead to gastrointestinal, breast, thyroid, endometrial and colon cancers.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1936 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200151 is selected from a sequence within the N-term region of human BMPR1A. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C77H126N22O34S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Signal Transduction, Signaling Molecules and Interaction
Alternate Names: Bone morphogenetic protein receptor type IA; Serine/threonine-protein kinase receptor R5; SKR5; Activin receptor-like kinase 3; ALK-3; CD292 antigen; BMPR1A; ACVRLK3
Accession No.: P36894, NP_004320
Description:
Upon ligand binding, BMPR1A forms a receptor complex consisting of two type II and two type I transmembrane Ser/Thr kinases. The type I receptors are activated by the type II receptors by using a phosphorylation mechanism, and subsequently bind SMAD transcriptional regulators. Defects in BMPR1A are the cause of juvenile polyposis syndrome, Cowden disease and hereditary mixed polyposis syndrome 2, which lead to gastrointestinal, breast, thyroid, endometrial and colon cancers.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1936 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200151 is selected from a sequence within the N-term region of human BMPR1A. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C77H126N22O34S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review